SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss its high short interest and potential for a squeeze, especially with Tether's increased ownership and advertising commitments. The community is also focused on the upcoming launch of Rumble Wallet and the company's acquisition of Northern Data, anticipating a potential shift in the company's valuation. Additionally, mentions of ties to Trump and the White House are circulating, influencing sentiment.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is gaining traction as discussions revolve around a potential Coinbase acquisition of a Solana trading platform. Community members are also actively discussing meme coins built on the Solana network, with some comparing it to Bitcoin. Technical analysis suggests a possible breakout, with focus on institutional buying.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai (FET) is trending as traders analyze its potential within the AI sector and speculate on upcoming movements, particularly in relation to Bitcoin's performance. Community members are weighing bullish scenarios and potential breakout points, while also considering recent news and technical analysis to gauge entry and exit points. Discussions also include perspectives on Fetch.ai's long-term potential in the decentralized AI space.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction, with the community highlighting its roots on the Solana blockchain and its cultural ties to the cannabis industry. Many allude to the token's potential, drawing parallels to Bitcoin and promoting it as more than just a memecoin. Community members are actively sharing information on how to acquire $WEEDCOIN and engage with the project.

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

mF International ($MFI) is trending due to a recently announced private placement of $500 million to launch a digital asset treasury strategy, sparking high trading volume and price volatility. Community members are debating the implications of this move, with some anticipating a potential short squeeze while others caution about the risks associated with pump-and-dump schemes often seen with Hong Kong-based companies. The discussions also involve comparisons to other stocks and speculation about future price movements, reflecting a divided sentiment among investors.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is trending as the community discusses potential partnerships and its integration with NatPay, which gives Zebec access to real-world payment infrastructure. Bullish sentiment is fueled by the possibility of major exchange listings and the potential for ISO 20022 compliance. However, some traders express concerns about token unlocks and broader market volatility.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as the community rallies around its meme-driven culture and infectious theme on the Solana blockchain. Discussions highlight the coin's potential for growth and strong community engagement, with many noting its connection to the $PUMP ecosystem. The community emphasizes a fun, meme-focused approach, aiming to spread the "infection" and build a strong presence.

Intuition is the L2 for trusted data, and the world's first token-curated graph—allowing people and machines to get the information they need, when they need it, from the sources they trust. With Intuition, you can put your 'intuition' to work—transforming your thoughts, opinions, and experiences into fuel for personalized AI, recommendations, and ads that truly understand you. You fully control your digital identity and data—the most valuable resources of the digital age—enabling you to fully leverage their value while unlocking and democratizing trillions in economic potential. Bring your social graphs, preferences, and 'intuition' with you wherever you go. No more rebuilding your profile and connections from scratch on every new platform—create and curate a universal, portable identity and context that allows applications and AI across the web to understand you instantly. And as you contribute, you’re not just improving your own experience—you’re enhancing the web for everyone who follows and trusts your perspective.

Trust Community Token

Trust Community Token ($TRUST) is garnering attention, with some users citing its recent listing on Coinbase and potential for high-volume swings. The community is discussing the token's fundamentals, including its tokenomics and development plans, while also pointing out chart discrepancies. Others express concerns, with some users reporting issues with purchasing and questioning the project's progress.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending due to high volume and upcoming presentation of Phase 3 data, igniting speculation of a potential squeeze. Community chatter highlights low float, significant institutional ownership, and comparisons to other Steve Cohen-backed stocks like CDTX. Some traders suggest the company may be a takeover target, given its current financial position and potential for FDA approval.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott is trending due to its planned acquisition of Exact Sciences ($EXAS) for approximately $23 billion, with community discussions focusing on the deal's potential impact on Abbott's cancer diagnostics business and whether a bidding war could emerge. The community is analyzing the strategic rationale and potential synergies, particularly regarding cancer screening technologies. Options traders are actively trading ABT calls and puts, indicating expectations for near-term volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Moderna (NASDAQ:MRNA) Sets New 12-Month Low - Here's Why

Moderna (NASDAQ:MRNA) Reaches New 12-Month Low - Here's Why...

Top Biotech Stocks To Consider - November 20th

Abivax, Cidara Therapeutics, Danaher, Vertex Pharmaceuticals, argenex, Moderna, and Cogent Biosciences are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

22,410 Shares in Moderna, Inc. $MRNA Acquired by Catalyst Funds Management Pty Ltd

Catalyst Funds Management Pty Ltd bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the...

Walmart, Intuit, The Gap, SanDisk And Moderna: Why These 5 Stocks Are On Investors' Radars Today

WMT, INTU, GAP, SNDK, MRNA were the stocks seen trending on Thursday, Nov. 20, 2025.read more...

What's Going On With Moderna Stock?

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business strategy.read more...

<ul class="summary-bullets"><li>Moderna said that the five-year term loan facility will strengthen its balance sheet and provide increased flexibility going forward.&nbsp;</li><li>The company continues to target cash breakeven by 2028 and to reduce its expected cash costs for 2026 and 2027.</li><li>It will build a vaccine franchise with as many as six approved products by 2028 and invest cash generated to diversify its portfolio. &nbsp;</li></ul>Vaccine maker Moderna (MRNA) said on Thursday that it has secured a $1.5 billion, five-year credit facility from Ares Management Credit Funds as it seeks to pivot into oncology and rare-disease therapeutics.The company is now eyeing 10% revenue growth in 2026. It said that the five-year term loan facility will strengthen its balance sheet and provide increased flexibility going forward.The initial tranche of $600 million, of three tranches, will be drawn upfront, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=9002529460187539&amp;symbol=MRNA">said</a>, followed by the option to avail $400 million through November 2027. The company can also draw another $500 million through November 2028 under the credit facility contingent on the achievement of key regulatory milestones.<h2 class="st-heading-2">Moderna’s Near-Term Goals</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5758345706655596&amp;symbol=MRNA">continues</a> to target cash breakeven by 2028 and reduce its 2026 and 2027 expected cash costs with cost management and by prioritizing certain research and development efforts.Moderna rose to fame during the COVID-19 pandemic with its mRNA-based vaccine Spikevax. In the third quarter of 2025, the company reported total revenue of $1 billion, down from $1.9 billion in the corresponding period of 2024, mainly due to lower COVID-19 vaccine sales. However, Covid vaccine sales accounted for a whopping 97% of the company’s overall revenue in the three months through the end of September."Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics," CEO Stéphane Bancel said on Thursday.The company will build a vaccine franchise with as many as six approved products by 2028 and invest cash generated from its portfolio, including Spikevax, mRESVIA and mNEXSPIKE, as well as other yet-to-launch vaccines, including a flu-covid combination vaccine, into diversifying its portfolio.Investment in late-stage oncology and rare disease programs will set the company up for additional growth in 2027 and 2028, the company said.Moderna’s pipeline currently consists of two oncology therapies and two rare disease therapeutics that are under development. It discontinued four programs, including those for congenital Cytomegalovirus, herpes simplex virus, Varicella-Zoster virus and Glycogen Storage Disease Type 1a (GSD1a) as part of its efforts to prioritize some research investments.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> remained in the ‘bearish’ territory, while message volume dropped from ‘low’ to ‘extremely low’.MRNA stock is down by 42% this year and by 35% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pacs-group-stock-soars-premarket-on-completion-of-audit-commitee-probe-upbeat-full-year-guidance/cLPAjZFREa9">PACS Group Stock Soars Premarket On Completion Of Audit Committee Probe, Upbeat Full-Year Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Secures $1.5B Credit Facility As It Seeks To Pivot Away From Vaccines

The company is now eyeing 10% revenue growth in 2026.

Equity

<ul class="summary-bullets"><li>According to Moderna, the onshoring will support both commercial and clinical supply and create hundreds of jobs with over $140 million in investment.&nbsp;</li><li>The new investment is aimed at allowing the company to control the entire production process.</li><li>Other popular pharma companies have also recently committed large amounts to expanding U.S. manufacturing, including Pfizer, Eli Lilly, and Johnson &amp; Johnson.</li></ul>Moderna, Inc. (MRNA) on Wednesday announced that it will bring drug product manufacturing to its existing Moderna Technology Center in Norwood, Massachusetts, as it seeks to operate end-to-end manufacturing for its mRNA medicines in the U.S."By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.," <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5477880263899463&amp;symbol=MRNA">said</a> CEO Stéphane Bancel. According to Cambridge-based Moderna, the onshoring will support both commercial and clinical supply and create hundreds of jobs with over $140 million in investment.<h2 class="st-heading-2">Timeline For New Facility</h2>The company said it has commenced construction at the facility in Massachusetts to incorporate drug product manufacturing capability, which is slated for completion in the first half of 2027.The move comes as the company seeks to reduce its reliance on contract manufacturers. The new investment is aimed at allowing the company to control the entire production process.Other popular pharma companies have also recently committed large amounts to expanding U.S. manufacturing, including Pfizer, Eli Lilly, and Johnson &amp; Johnson, as they seek to reduce reliance on overseas manufacturing.<h2 class="st-heading-2">Moderna’s mRNA Candidates</h2>Moderna rose to fame during the COVID-19 pandemic with its mRNA-based vaccine Spikevax. In the third quarter of 2025, the company reported total revenue of $1 billion, down from $1.9 billion in the corresponding period of 2024, mainly due to lower COVID-19 vaccine sales.However, Covid vaccine sales accounted for a whopping 97% of the company’s overall revenue in the three months through the end of September.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> is down 41% this year and 34% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kzia-stock-soars-after-company-stage-iv-cancer-patients-shows-initial-complete-remission-on-its-drug-combination/cLPoQdMREBN">KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Brings Back Drug Product Manufacturing To Home Ground

The company said it has commenced construction at the Massachusetts facility, which is slated for completion in the first half of 2027.

If Demographics Are Destiny... We're Screwed!

If Demographics Are Destiny... We're Screwed! Authored by Jim Quinn via The Burning Platform blog, Demographics don't lie. The governments of the world and their captured bureaucrats can manipulate...

Moderna, Inc. $MRNA Stock Position Lifted by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. boosted its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 2.4% in the second quarter, according to the company in its most recent filing with the Securities...

MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?

Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNAModerna Inc